Skip to main content
Equibles

Max Rosett

CFO

Immunome Inc. (IMNM)
Immunome Inc. (IMNM)

Equibles does not estimate personal net worth.

Get an email with a short summary when Immunome Inc. publishes a filing, an earnings call transcript or a press release.

Get IMNM alerts

About Max Rosett

Max Rosett is recorded as CFO at Immunome Inc. (IMNM). The newest filing on record that lists Max Rosett as CFO at Immunome Inc. (IMNM) is dated April 24, 2026. Immunome Inc. reported in an 8-K filed December 29, 2023 that Max Rosett was appointed Interim Chief Financial Officer and principal financial officer, effective January 2, 2024. Max Rosett has spoken on 1 investor event across 1 company, most recently for Immunome Inc. on June 9, 2026. Immunome Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Immunome Inc. includes Clay B. Siegall, Ph.D. (CEO), Clay Siegall (CEO), Corleen Roche (CFO) and 7 others.

“The Company's board of directors has, effective as of the Roche Separation Date, appointed Max Rosett, in addition to his other titles, as the Company's Interim Chief Financial Officer and principal financial officer.”
Immunome Inc. Form 8-K, filed December 29, 2023 · Read the filing

Max Rosett on recent calls

“As you said, Immunome is a targeted oncology company, and there really are two pillars to this story. We view varagastestep, our gamma secretase inhibitor, for which we recently submitted an NDA, as a fantastic asset.”
CFO, Goldman Sachs 47th Annual Global Healthcare Conference ·

Affiliation history

Company network

Leadership on record at Immunome Inc.

Recent activity